As part of the event, J.D. Finley, Chief Executive Officer of Palisade Bio, will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed. About Palisade Bio Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical com ...

Core Insights - PALI-2108 is a promising orally delivered, colon-specific PDE4 inhibitor prodrug for Ulcerative Colitis (UC) treatment, demonstrating safety, efficacy, and tolerability in preclinical studies [1][3][8] - The company plans to initiate Phase 1 human clinical trials for PALI-2108 by the end of 2024 [1] Group 1: Preclinical Data and Efficacy - Preclinical studies showed PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to intolerable doses of apremilast for human use [1][8] - Significant advancements were made in assessing on-target PDE4 binding within colon tissue, utilizing a cellular thermal shift assay (CETSA) [3] - In a DSS colitis mouse model, PALI-2108 significantly prevented colon length reduction and improved various disease activity scores in a dose-dependent manner [8] Group 2: Safety and Therapeutic Window - PALI-2108 demonstrated no systemic toxicity in dogs, indicating a large therapeutic window due to its local activation [8] - A single oral dose of PALI-2108 prevented emesis observed with lower doses of the active PDE4 moiety, showcasing an enhanced therapeutic profile [5][8] Group 3: Company Overview - Palisade Bio is focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, aiming to transform treatment landscapes with targeted approaches [9]

The poster titled, "Local Bioactivation and efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment," is being presented by Dr. Mitch Jones as part of the Animal Models of IBD: Pre- Clinical Treatment of Intestinal Inflammation session being held today, May 21, 2024. The poster is available on the Scientific Publications page of the Company's website. "The findings from this preclinical study add to our growing body of encouraging data for PALI-2108 and further bolster our ...

Carlsbad, CA, May 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the first quarter 2024 and provided a business update. Recent Highlights "Our team remains focused on advancing PALI-2108 towards our first-in-human study, which is on track to start late ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to Commission File Number: 001-33672 PALISADE BIO, INC. (Exact name of registrant as specified in its charter) Delaware 52-2007292 (State or other jurisdictio ...

NASDAQ: PALI | palisadebio.com 100 Protecting Intestinal Barrier Health July 2022 Corporate Presentation Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans, expected near-term Phase 2 and Phase 3 milestones (including but not limited to, enrollment completion), hypothesis leading to adhesion formation, ...